JW Pharmaceutical Corporation (001065.KS)
KRW 29450.0
(-1.01%)
KRW 29450.0
(-1.01%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 106.09 Billion KRW | -4.99% |
| 2022 | 111.66 Billion KRW | 8.92% |
| 2021 | 102.52 Billion KRW | 1.31% |
| 2020 | 101.19 Billion KRW | 11.89% |
| 2019 | 90.44 Billion KRW | -10.78% |
| 2018 | 101.36 Billion KRW | -4.93% |
| 2017 | 106.62 Billion KRW | 9.27% |
| 2016 | 97.58 Billion KRW | 18.38% |
| 2015 | 82.43 Billion KRW | 15.54% |
| 2014 | 71.34 Billion KRW | -5.01% |
| 2013 | 75.11 Billion KRW | 7.09% |
| 2012 | 70.13 Billion KRW | -18.37% |
| 2011 | 85.91 Billion KRW | -5.32% |
| 2010 | 90.74 Billion KRW | -7.95% |
| 2009 | 98.58 Billion KRW | 29.11% |
| 2008 | 76.35 Billion KRW | 38.55% |
| 2007 | 55.11 Billion KRW | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 111.83 Billion KRW | 5.41% |
| 2024 Q2 | 110.58 Billion KRW | -1.11% |
| 2023 Q1 | 118.97 Billion KRW | 6.55% |
| 2023 Q2 | 118.63 Billion KRW | -0.29% |
| 2023 FY | 106.09 Billion KRW | -4.99% |
| 2023 Q3 | 112.79 Billion KRW | -4.92% |
| 2023 Q4 | 106.09 Billion KRW | -5.95% |
| 2022 Q4 | 111.66 Billion KRW | 1.11% |
| 2022 Q2 | 111.48 Billion KRW | 4.1% |
| 2022 Q3 | 110.43 Billion KRW | -0.94% |
| 2022 Q1 | 107.09 Billion KRW | 4.46% |
| 2022 FY | 111.66 Billion KRW | 8.92% |
| 2021 Q3 | 109.97 Billion KRW | 1.38% |
| 2021 FY | 102.52 Billion KRW | 1.31% |
| 2021 Q1 | 104.84 Billion KRW | 3.61% |
| 2021 Q4 | 102.52 Billion KRW | -6.77% |
| 2021 Q2 | 108.47 Billion KRW | 3.46% |
| 2020 Q2 | 112.27 Billion KRW | 3.05% |
| 2020 Q1 | 108.95 Billion KRW | 20.47% |
| 2020 Q3 | 109.58 Billion KRW | -2.39% |
| 2020 Q4 | 101.19 Billion KRW | -7.66% |
| 2020 FY | 101.19 Billion KRW | 11.89% |
| 2019 Q2 | 108.9 Billion KRW | 6.04% |
| 2019 Q1 | 102.7 Billion KRW | 1.32% |
| 2019 FY | 90.44 Billion KRW | -10.78% |
| 2019 Q3 | 105.66 Billion KRW | -2.98% |
| 2019 Q4 | 90.44 Billion KRW | -14.4% |
| 2018 Q3 | 110.86 Billion KRW | 0.36% |
| 2018 Q2 | 110.47 Billion KRW | 3.31% |
| 2018 Q1 | 106.92 Billion KRW | 0.28% |
| 2018 FY | 101.36 Billion KRW | -4.93% |
| 2018 Q4 | 101.36 Billion KRW | -8.57% |
| 2017 Q3 | 103.02 Billion KRW | -0.84% |
| 2017 Q2 | 103.88 Billion KRW | -0.84% |
| 2017 Q1 | 104.77 Billion KRW | 7.36% |
| 2017 Q4 | 106.62 Billion KRW | 3.5% |
| 2017 FY | 106.62 Billion KRW | 9.27% |
| 2016 FY | 97.58 Billion KRW | 18.38% |
| 2016 Q1 | 79.31 Billion KRW | -3.78% |
| 2016 Q2 | 81.77 Billion KRW | 3.1% |
| 2016 Q3 | 86.72 Billion KRW | 6.05% |
| 2016 Q4 | 97.58 Billion KRW | 12.52% |
| 2015 Q2 | 70.29 Billion KRW | 3.62% |
| 2015 Q1 | 67.83 Billion KRW | -4.92% |
| 2015 Q4 | 82.43 Billion KRW | 12.0% |
| 2015 Q3 | 73.6 Billion KRW | 4.71% |
| 2015 FY | 82.43 Billion KRW | 15.54% |
| 2014 Q2 | 76.22 Billion KRW | -8.95% |
| 2014 Q1 | 83.71 Billion KRW | 11.46% |
| 2014 Q3 | 73.73 Billion KRW | -3.27% |
| 2014 Q4 | 71.34 Billion KRW | -3.24% |
| 2014 FY | 71.34 Billion KRW | -5.01% |
| 2013 FY | 75.11 Billion KRW | 7.09% |
| 2013 Q4 | 75.11 Billion KRW | 17.57% |
| 2013 Q3 | 63.89 Billion KRW | -7.92% |
| 2013 Q2 | 69.38 Billion KRW | -1.95% |
| 2013 Q1 | 70.77 Billion KRW | 0.9% |
| 2012 Q1 | 89.22 Billion KRW | 0.0% |
| 2012 FY | 70.13 Billion KRW | -18.37% |
| 2012 Q4 | 70.13 Billion KRW | 0.0% |
| 2011 FY | 85.91 Billion KRW | -5.32% |
| 2011 Q3 | 92.76 Billion KRW | 5.62% |
| 2011 Q1 | 89.66 Billion KRW | -1.19% |
| 2011 Q2 | 87.82 Billion KRW | -2.05% |
| 2010 Q1 | 101.95 Billion KRW | 3.43% |
| 2010 Q2 | 106.27 Billion KRW | 4.23% |
| 2010 FY | 90.74 Billion KRW | -7.95% |
| 2010 Q4 | 90.74 Billion KRW | -11.31% |
| 2010 Q3 | 102.31 Billion KRW | -3.72% |
| 2009 Q1 | 109.82 Billion KRW | 43.83% |
| 2009 Q4 | 98.58 Billion KRW | -12.77% |
| 2009 Q3 | 113 Billion KRW | -0.17% |
| 2009 FY | 98.58 Billion KRW | 29.11% |
| 2009 Q2 | 113.19 Billion KRW | 3.07% |
| 2008 FY | 76.35 Billion KRW | 38.55% |
| 2008 Q4 | 76.35 Billion KRW | -2.26% |
| 2008 Q3 | 78.12 Billion KRW | 5.4% |
| 2008 Q2 | 74.12 Billion KRW | 8.52% |
| 2008 Q1 | 68.3 Billion KRW | 23.94% |
| 2007 Q4 | 55.11 Billion KRW | 15.84% |
| 2007 FY | 55.11 Billion KRW | 0.0% |
| 2007 Q2 | 49.31 Billion KRW | 0.63% |
| 2007 Q1 | 49 Billion KRW | 0.0% |
| 2007 Q3 | 47.57 Billion KRW | -3.53% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 44.15 Billion KRW | -140.286% |
| Dong-A Socio Holdings Co., Ltd. | 117.85 Billion KRW | 9.979% |
| Ildong Holdings Co., Ltd. | 91.16 Billion KRW | -16.371% |
| HANDOK Inc. | 94.46 Billion KRW | -12.308% |
| Kukje Pharma Co., Ltd. | 21.24 Billion KRW | -399.416% |
| Yuhan Corporation | 284.75 Billion KRW | 62.743% |
| Dong-A ST Co., Ltd. | 116.31 Billion KRW | 8.789% |
| SAMSUNG PHARM. Co., LTD. | 16.25 Billion KRW | -552.521% |
| Hanmi Pharm. Co., Ltd. | 288.81 Billion KRW | 63.267% |
| Hanall Biopharma Co.,Ltd | 32.38 Billion KRW | -227.603% |
| Ilyang Pharmaceutical Co.,Ltd | 61.72 Billion KRW | -71.878% |
| Dong Sung Bio Pharm.Co.,Ltd. | 19.47 Billion KRW | -444.699% |
| MYUNGMOON Pharm co.,Ltd | 30.28 Billion KRW | -250.365% |
| Hana Pharm Co., Ltd. | 48.34 Billion KRW | -119.436% |
| Yuyu Pharma, Inc. | 44.15 Billion KRW | -140.286% |
| Ilsung Pharmaceuticals Co., Ltd. | 31.24 Billion KRW | -239.593% |
| REYON Pharmaceutical Co., Ltd. | 35.17 Billion KRW | -201.598% |
| Aprogen pharmaceuticals,Inc. | 48.12 Billion KRW | -120.435% |
| JW Holdings Corporation | 147.58 Billion KRW | 28.117% |
| Ildong Pharmaceutical Co., Ltd. | 84.62 Billion KRW | -25.369% |
| Chong Kun Dang Pharmaceutical Corp. | 261.43 Billion KRW | 59.419% |
| Shin Poong Pharm.Co.,Ltd. | 53.92 Billion KRW | -96.745% |
| Hyundai Pharmaceutical Co., Ltd. | 26.99 Billion KRW | -292.96% |
| Samil Pharmaceutical Co.,Ltd | 32.51 Billion KRW | -226.32% |
| Jeil Pharmaceutical Co.,Ltd | 109.76 Billion KRW | 3.35% |
| Yuyu Pharma, Inc. | 44.15 Billion KRW | -140.286% |
| Kwang Dong Pharmaceutical Co., Ltd. | 188.64 Billion KRW | 43.761% |
| Daewoong pharmaceutical Co.,Ltd | 241.54 Billion KRW | 56.078% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 0.0% |
| Yuhan Corporation | 284.75 Billion KRW | 62.743% |
| Jeil Pharma Holdings Inc | 125.28 Billion KRW | 15.317% |
| Yungjin Pharm. Co., Ltd. | 61.98 Billion KRW | -71.152% |
| Suheung Co., Ltd. | 259.84 Billion KRW | 59.171% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 0.0% |
| Samjin Pharmaceuticals Co., Ltd. | 79.6 Billion KRW | -33.276% |
| Korea United Pharm Inc. | 49.14 Billion KRW | -115.887% |
| CKD Bio Corp. | 69.08 Billion KRW | -53.573% |
| Daewon Pharmaceutical Co., Ltd. | 105.07 Billion KRW | -0.964% |
| Dongwha Pharm.Co.,Ltd | 70.69 Billion KRW | -50.064% |
| Whan In Pharm Co.,Ltd. | 54.05 Billion KRW | -96.255% |
| Shin Poong Pharm.Co.,Ltd. | 53.92 Billion KRW | -96.745% |
| Chong Kun Dang Holdings Corp. | 194.76 Billion KRW | 45.529% |
| Boryung Corporation | 189.8 Billion KRW | 44.105% |
| Bukwang Pharmaceutical Co., Ltd. | 56.83 Billion KRW | -86.676% |
| Ilyang Pharmaceutical Co.,Ltd | 61.72 Billion KRW | -71.878% |
| JW Lifescience Corporation | 23.39 Billion KRW | -353.409% |